UY33491A - ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. - Google Patents
?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.Info
- Publication number
- UY33491A UY33491A UY0001033491A UY33491A UY33491A UY 33491 A UY33491 A UY 33491A UY 0001033491 A UY0001033491 A UY 0001033491A UY 33491 A UY33491 A UY 33491A UY 33491 A UY33491 A UY 33491A
- Authority
- UY
- Uruguay
- Prior art keywords
- medicine
- pharmaceutically acceptable
- sulfonamide derivatives
- acceptable salts
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La invención se refiere a derivados de sulfonamida, a su uso en medicina, a composiciones que los contienen, a procesos para su preparación y a intermediarios usados en dichos procesos. Más en particular, la invención se refiere a nuevos inhibidores de Nav1.7 de sulfonamida de la Fórmula (I) o una sal de este farmacéuticamente aceptable, en donde Z1, Ra, Rb, R1, R2, R3, R4 y R5 son como se definen en la descripción. Los inhibidores de Nav 1.7 son potencialmente útiles para el tratamiento de un amplio rango de trastornos, en particular, del dolor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36292710P | 2010-07-09 | 2010-07-09 | |
US201161492525P | 2011-06-02 | 2011-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33491A true UY33491A (es) | 2012-02-29 |
Family
ID=45439019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033491A UY33491A (es) | 2010-07-09 | 2011-07-07 | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. |
Country Status (8)
Country | Link |
---|---|
US (1) | US8772293B2 (es) |
EP (1) | EP2590951B1 (es) |
JP (1) | JP5830534B2 (es) |
AR (1) | AR082201A1 (es) |
CA (1) | CA2804593C (es) |
ES (1) | ES2533065T3 (es) |
UY (1) | UY33491A (es) |
WO (1) | WO2012004743A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
ES2526675T3 (es) | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
JP2013536165A (ja) | 2010-07-12 | 2013-09-19 | ファイザー・リミテッド | 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体 |
ES2526541T3 (es) | 2010-07-12 | 2015-01-13 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje |
CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP2593431B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
KR20140091022A (ko) * | 2011-10-31 | 2014-07-18 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
JP6014155B2 (ja) * | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
WO2013137371A1 (ja) * | 2012-03-15 | 2013-09-19 | 興和株式会社 | 新規ピリミジン化合物及びそれらを含有する医薬 |
WO2013161928A1 (ja) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | オキサゾロトリアゾール誘導体およびそれらを含有する医薬組成物 |
MX2014014234A (es) | 2012-05-22 | 2015-05-07 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor. |
CA2878478A1 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
ES2828503T3 (es) * | 2012-10-15 | 2021-05-26 | Dae Woong Pharma | Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos |
CN104869992A (zh) * | 2012-10-26 | 2015-08-26 | 默沙东公司 | 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 |
WO2014153037A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Substituted triazolopyridines and methods of use thereof |
RU2015143834A (ru) | 2013-03-15 | 2017-04-24 | Дженентек, Инк. | Замещенные бензоксазолы и способы их применения |
JP6449845B2 (ja) * | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
AU2014318979B2 (en) * | 2013-09-10 | 2019-03-28 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
EP3074377B1 (en) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
US10468036B2 (en) * | 2014-04-30 | 2019-11-05 | Accusonus, Inc. | Methods and systems for processing and mixing signals using signal decomposition |
JP2017516803A (ja) | 2014-05-30 | 2017-06-22 | ファイザー・インク | ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド |
CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
MX2017014715A (es) | 2015-05-22 | 2018-03-16 | Genentech Inc | Benzamidas sustituidas y metodos para utilizarlas. |
JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック, インコーポレイテッド | 治療化合物及びその使用方法 |
CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
US10316026B2 (en) | 2015-11-06 | 2019-06-11 | Daiichi Sankyo Company, Limited | Method for removing dimethoxybenzyl group |
MA43304A (fr) | 2015-11-25 | 2018-10-03 | Genentech Inc | Benzamides substitués utiles en tant que bloqueurs de canaux sodiques |
KR20180095598A (ko) | 2015-12-18 | 2018-08-27 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 히드록시알킬아민- 및 히드록시시클로알킬아민-치환된 디아민-아릴술폰아미드 화합물 |
EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
US10246453B2 (en) | 2016-05-20 | 2019-04-02 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
SG11201903348UA (en) | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
CA3042004A1 (en) | 2016-12-09 | 2018-06-14 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
WO2018175707A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
AU2019331005B2 (en) | 2018-08-31 | 2024-03-28 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
CA3104913A1 (en) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
EP3891157A4 (en) | 2018-12-05 | 2022-08-31 | Merck Sharp & Dohme Corp. | 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS |
TW202216671A (zh) * | 2020-06-25 | 2022-05-01 | 瑞士商諾華公司 | 1,4—二取代的嗒𠯤化合物之製造方法 |
WO2023122494A1 (en) * | 2021-12-23 | 2023-06-29 | Veralox Therapeutics | Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR71915B (es) | 1979-11-27 | 1983-08-16 | Pfizer | |
EP0194599A3 (en) | 1985-03-14 | 1988-01-20 | Nissan Chemical Industries Ltd. | Benzamide derivatives, process for producing the same, and soil fungicides containing the same |
WO1988001133A1 (en) | 1986-08-20 | 1988-02-25 | Fmc Corporation | Herbicides |
US5084085A (en) | 1986-08-20 | 1992-01-28 | Fmc Corporation | Herbicidal aryloxyphenyltriazolinones and related compounds |
US4845264A (en) | 1987-03-05 | 1989-07-04 | Teijin Limited | Phenoxycarboxylic acid and herbicide comprising it as active ingredient |
US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
US4920130A (en) | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
US4920133A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
DE68909958D1 (de) | 1988-01-19 | 1993-11-25 | Tanabe Seiyaku Co | Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung. |
GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
NO903525L (no) | 1989-08-11 | 1991-02-12 | Ici Plc | Nitrogenforbindelser. |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
WO1993000332A1 (en) | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
GB2266527A (en) | 1992-03-17 | 1993-11-03 | Merck & Co Inc | Substituted azetidinones useful in the treatment of leukemia |
JPH05289262A (ja) | 1992-04-10 | 1993-11-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
JPH05307242A (ja) | 1992-04-28 | 1993-11-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
JP3101848B2 (ja) | 1992-05-15 | 2000-10-23 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
FR2694295B1 (fr) | 1992-07-28 | 1994-09-02 | Adir | Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent. |
AU5802894A (en) | 1992-12-17 | 1994-07-04 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
ATE189217T1 (de) | 1993-03-19 | 2000-02-15 | Merck & Co Inc | Phenoxyphenylessigsäurederivate |
JPH06347968A (ja) | 1993-04-14 | 1994-12-22 | Fuji Photo Film Co Ltd | ハロゲン化銀感光材料 |
DK77393D0 (da) | 1993-06-29 | 1993-06-29 | Novo Nordisk As | Aktivering af enzymer |
JP3503839B2 (ja) | 1994-05-25 | 2004-03-08 | 富士写真フイルム株式会社 | ポジ型感光性組成物 |
EP0774965A4 (en) | 1994-08-08 | 1997-10-29 | Merck & Co Inc | PHENOXYPHENYLACETIC ACID DERIVATIVES |
AU3642795A (en) | 1994-09-27 | 1996-04-19 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
GB9514031D0 (en) | 1995-07-10 | 1995-09-06 | Zeneca Ltd | Chemical process |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
JP3519218B2 (ja) | 1996-08-14 | 2004-04-12 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料および画像形成方法 |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
CN1268942A (zh) | 1997-06-27 | 2000-10-04 | 藤泽药品工业株式会社 | 磺酰胺化合物及其药物用途 |
US6555584B1 (en) | 2000-06-29 | 2003-04-29 | Ajinomoto Co., Inc. | Acylsulfonamide derivative |
DE19742951A1 (de) | 1997-09-29 | 1999-04-15 | Hoechst Schering Agrevo Gmbh | Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung |
CA2306825A1 (en) | 1997-10-17 | 1999-04-29 | Avantis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
US6268387B1 (en) | 1997-12-23 | 2001-07-31 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
GB9805520D0 (en) | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
GT199900044A (es) | 1998-04-10 | 2000-09-14 | Procedimientos para preparar haluros de fenoxifenilsulfonilo. | |
DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
NZ515087A (en) | 1999-04-28 | 2003-11-28 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
WO2000066120A1 (en) | 1999-05-05 | 2000-11-09 | Merck & Co., Inc. | Novel catechols as antimicrobial agents |
EP1183234A1 (en) | 1999-05-24 | 2002-03-06 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
AU5723500A (en) | 1999-05-24 | 2000-12-12 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
WO2000071507A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
JP2001075213A (ja) | 1999-09-07 | 2001-03-23 | Fuji Photo Film Co Ltd | ハロゲン化銀写真乳剤、その製造方法及びこれを用いたハロゲン化銀写真感光材料 |
JP2003510304A (ja) | 1999-09-29 | 2003-03-18 | ノボ ノルディスク アクティーゼルスカブ | 新規芳香族化合物 |
AU769430B2 (en) | 1999-10-13 | 2004-01-29 | Pfizer Products Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
KR20020081424A (ko) | 2000-03-09 | 2002-10-26 | 아벤티스 파마 도이칠란트 게엠베하 | Ppar 매개인자의 치료학적 용도 |
US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
EP1260221A3 (en) | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Combination treatment for depression and anxiety |
SE0101978D0 (sv) | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | New compounds |
WO2003042150A1 (fr) | 2001-11-16 | 2003-05-22 | Toyama Chemical Co., Ltd. | Nouveaux derives de benzophenone ou sels de ceux-ci |
US20050288346A1 (en) | 2002-08-26 | 2005-12-29 | Cube Rowena V | Acetophenone potentiators of metabotropic glutamate receptors |
EP1558245A2 (en) | 2002-10-28 | 2005-08-03 | Novo Nordisk A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
CA2516078C (en) | 2003-02-28 | 2014-04-29 | Oxigene, Inc. | Catechol compositions and use thereof |
WO2005013914A2 (en) | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
ZA200605526B (en) | 2004-02-12 | 2007-11-28 | Transtech Pharma Inc | Substituted azole derivatives, compositions and methods of use |
GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
AU2005245386B2 (en) | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
CA2574971A1 (en) | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
US7956191B2 (en) | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
EP2305640A3 (en) | 2005-12-15 | 2011-07-20 | AstraZeneca AB | Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases |
JP2009057282A (ja) | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
US20080004282A1 (en) | 2006-04-10 | 2008-01-03 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
DK2076508T3 (da) | 2006-10-18 | 2011-02-21 | Pfizer Prod Inc | Biaryl-ether-urinstof-forbindelser |
PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
WO2008118758A1 (en) | 2007-03-23 | 2008-10-02 | Icagen, Inc. | Inhibitors of ion channels |
BRPI0810202A2 (pt) | 2007-05-03 | 2014-10-21 | Pfizer Ltd | Derivados de piridina |
MX2009013355A (es) | 2007-06-07 | 2010-02-22 | Astellas Pharma Inc | Compuesto de piridona. |
US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
US8389734B2 (en) | 2007-10-11 | 2013-03-05 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
TW200930368A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
WO2009067541A2 (en) | 2007-11-20 | 2009-05-28 | Gilead Sciences, Inc. | Integrase inhibitors |
EP2674417A3 (en) | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating inflammation |
GB0725214D0 (en) | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
JP2011514326A (ja) | 2008-02-15 | 2011-05-06 | ビーエーエスエフ ソシエタス・ヨーロピア | 置換スルホン酸アミド化合物 |
EP2119690A1 (en) | 2008-05-14 | 2009-11-18 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Radiolabelled MMP selective compounds |
BRPI0912109A2 (pt) | 2008-05-28 | 2015-07-28 | Basf Se | Composto, processo para preparar os mesmos, composições agroquímicas, método para combater fungos nocivos fitopatogênicos, uso dos compostos, e, semente |
CA2728511A1 (en) | 2008-06-23 | 2009-12-30 | Astellas Pharma Inc. | Sulfonamide compounds or salts thereof |
US8107894B2 (en) | 2008-08-12 | 2012-01-31 | Raytheon Company | Modular solid-state millimeter wave (MMW) RF power source |
DK2385938T3 (en) | 2009-01-12 | 2015-04-27 | Pfizer Ltd | Sulfonamidderivater |
JP5289262B2 (ja) | 2009-09-30 | 2013-09-11 | 京セラドキュメントソリューションズ株式会社 | シート搬送装置とこれを備えた画像読取装置及び画像形成装置 |
ES2526675T3 (es) * | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
EP2593431B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
JP2013536165A (ja) | 2010-07-12 | 2013-09-19 | ファイザー・リミテッド | 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体 |
CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
ES2526541T3 (es) | 2010-07-12 | 2015-01-13 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje |
CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
-
2011
- 2011-07-05 JP JP2013519189A patent/JP5830534B2/ja not_active Expired - Fee Related
- 2011-07-05 CA CA2804593A patent/CA2804593C/en not_active Expired - Fee Related
- 2011-07-05 EP EP11746620.1A patent/EP2590951B1/en not_active Not-in-force
- 2011-07-05 WO PCT/IB2011/052974 patent/WO2012004743A1/en active Application Filing
- 2011-07-05 ES ES11746620.1T patent/ES2533065T3/es active Active
- 2011-07-07 UY UY0001033491A patent/UY33491A/es not_active Application Discontinuation
- 2011-07-08 AR ARP110102479A patent/AR082201A1/es not_active Application Discontinuation
- 2011-07-08 US US13/178,534 patent/US8772293B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2590951B1 (en) | 2015-01-07 |
AR082201A1 (es) | 2012-11-21 |
EP2590951A1 (en) | 2013-05-15 |
CA2804593C (en) | 2015-11-24 |
JP5830534B2 (ja) | 2015-12-09 |
JP2013531031A (ja) | 2013-08-01 |
US20120010182A1 (en) | 2012-01-12 |
ES2533065T3 (es) | 2015-04-07 |
CA2804593A1 (en) | 2012-01-12 |
WO2012004743A1 (en) | 2012-01-12 |
US8772293B2 (en) | 2014-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
ECSP14013324A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
CR11857A (es) | Compuestos pirazolicos 436 | |
UY31468A1 (es) | Derivados bis-(sulfonilamino) en terapia 065 | |
CU20110145A7 (es) | Derivados de sulfonamida | |
CL2012001391A1 (es) | Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios. | |
DOP2014000133A (es) | Triazolopiridinas sustituidas | |
UY31481A1 (es) | Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones | |
NI201000085A (es) | Derivados bis - (sulfonilamino) en terapia 066. | |
UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
CR20170468A (es) | Compuestos novedosos | |
CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
UY35536A (es) | ?derivados de sulfonamida?. | |
ECSP22083772A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
DOP2021000103A (es) | Pirazoles como moduladores de hemoglobina | |
ECSP18056196A (es) | Derivados de indano | |
CU20100250A7 (es) | Compuestos pirazólicos 436 | |
AR113817A1 (es) | Compuestos útiles para inhibir a cdk7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200807 |